Kodiak Sciences Inc. (KOD)
Automate Your Wheel Strategy on KOD
With Tiblio's Option Bot, you can configure your own wheel strategy including KOD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol KOD
- Rev/Share 0.0
- Book/Share 2.0635
- PB 1.7543
- Debt/Equity 0.6214
- CurrentRatio 4.6212
- ROIC -0.6833
- MktCap 191003870.0
- FreeCF/Share -2.0365
- PFCF -1.7781
- PE -1.4338
- Debt/Assets 0.227
- DivYield 0
- ROE -0.8083
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | KOD | Jefferies | Hold | Buy | -- | $20 | Dec. 9, 2024 |
| Initiation | KOD | H.C. Wainwright | -- | Neutral | -- | $3 | Sept. 5, 2024 |
News
Why Is Kodiak Sciences (KOD) Up 10.5% Since Last Earnings Report?
Published: June 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock?
Read More
Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference
Published: May 29, 2025 by: PRNewsWire
Sentiment: Neutral
PALO ALTO, Calif. , May 29, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that Victor Perlroth, M.D.
Read More
Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Negative
KOD reports a wider-than-expected loss for the first quarter of 2025. The company provides updates regarding its pipeline development plans.
Read More
Kodiak Q4 Loss Narrower Than Expected, Pipeline Development in Focus
Published: March 28, 2025 by: Zacks Investment Research
Sentiment: Negative
KOD reports a narrower-than-expected loss for the fourth quarter of 2024. The company provides updates regarding its pipeline development plans.
Read More
Kodiak Sciences: Anti-VEGF Could Win Nicely On Retinal Disorders
Published: February 23, 2025 by: Seeking Alpha
Sentiment: Positive
Kodiak Sciences basically uses a novel biopolymer conjugate platform to develop more durable, next-generation retinal disease therapies. Today, KOD's pipeline includes Phase 3 candidates for DR, RVO, and wet AMD, targeting an $18 billion TAM by 2028. The main catalyst to watch now is their upcoming pivotal data in 2026 that could lead to FDA approval by 2027.
Read More
About Kodiak Sciences Inc. (KOD)
- IPO Date 2018-10-04
- Website https://kodiak.com
- Industry Biotechnology
- CEO Dr. Victor Perlroth M.D.
- Employees 109